U.S. Supreme Court Rejects Pharma Industry Challenge to Medicare Drug Price Plan

The U.S. Supreme Court on Monday declined to hear a major challenge from leading pharmaceutical companies against the Medicare drug price negotiation program introduced under former President Joe Biden’s Inflation Reduction Act of 2022. The decision leaves intact lower court rulings that upheld the federal government’s authority to negotiate prices for high-cost prescription drugs under Medicare.

Drugmakers including Novo Nordisk, AstraZeneca, Johnson & Johnson subsidiary Janssen Pharmaceuticals, Bristol Myers Squibb, Novartis, and Boehringer Ingelheim argued that the law unfairly forces companies to accept government-imposed discounts or face heavy financial penalties. The firms claimed the policy violates constitutional protections, including due process, property rights, and free speech, while also warning that reduced profits could harm future medical innovation.

The Medicare negotiation plan was designed to lower prescription drug costs for Americans, particularly senior citizens enrolled in Medicare. The first negotiated prices on 10 major drugs have already taken effect this year, with the Trump administration continuing to defend the program as part of broader efforts to reduce healthcare expenses. Officials from the Centers for Medicare & Medicaid Services stated the initiative targets some of the most expensive medications in the Medicare system, aiming to ease the financial burden on patients through lower out-of-pocket costs and premiums.

Pic Courtesy: google/ images are subject to copyright